by MM360 Staff | Dec 10, 2025 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Dec 10, 2025 | Uncategorized
Source: CURE articles Post Content Read More
by Josh Friedman | Dec 9, 2025 | Uncategorized
ORLANDO — “The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus daratumumab (Darzalex, Johnson & Johnson/Janssen) reduced the risk for disease progression or death 83% from standard...
by MM360 Staff | Dec 9, 2025 | Publications
Cureus. 2025 Dec 3;17(12):e98368. doi: 10.7759/cureus.98368. eCollection 2025 Dec. ABSTRACT Relapsed/refractory multiple myeloma (RRMM) remains a challenging condition with a need for more effective treatment options. There are ongoing clinical trials analyzing the...
by MM360 Staff | Dec 9, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
